uch larger trials are under way. When Johnson & Johnson unveiled data from its esketamine study in treatment-resistant depression at the American Psychiatric Association meeting in May, the presentation was jammed. Esketamine could become the first-ever rapid-acting antidepressant, and physicians and investors are c

e theoretically infinite number of ways that a personality can be, it is remarkable that the latest Diagnostic and Statistical Manual of the American Psychiatric Association, DMS-IV, describes only eight types, which form three subsets of exaggerated expressions of stable personality styles called personality disorders. A